pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights
Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation.
The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations. Highlights since the last update include:
- 7 products completed CADTH review, for a total of 11 files under consideration;
- 5 products initiated pCPA negotiations, for a total of 33 active negotiations;
- 5 negotiations completed for a total of 302 completed negotiations;
- 1 negotiation closed, for a total of 49 closed negotiations; and
- 1 file was closed without negotiation, for a total of 74 declined negotiations.
Files Under pCPA Consideration
7 new drug products received a CDEC recommendation or pERC notification to implement in February 2020, for a total of approximately 11 products under pCPA Consideration.
| Brand Name | Generic Name | Manufacturer | Indication | Recommendation |
|---|---|---|---|---|
| Rinvoq | Upadacitinib | AbbVie | Rheumatoid Arthritis | Conditional |
| Kadcyla | Trastuzumab Emtansine | Hoffmann-La Roche | Early Breast Cancer | Reimburse |
| Libtayo | Cemiplimab | Sanofi Genzyme | Cutaneous Squamous Cell Carcinoma | Conditional |
| Trintellix | Vortioxetine hydrobromide | Lundbeck | Major depressive disorder | Conditional |
| Vyndaqel | Tafamidis | Pfizer | Transthyretin-Mediated Amyloidosis | Conditional |
| Lorbrena | Lorlatinib | Pfizer | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse |
| Tecentriq | Atezolizumab | Hoffmann-La Roche | Small Cell Lung Cancer (SCLC) | Do not reimburse |
Negotiation Initiation
The pCPA initiated 5 new negotiations since the last update, for a total of 33 active negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Initiate |
|---|---|---|---|---|---|
| Botox | onabotulinumtoxinA | Allergan | Migraine, chronic | 17 Oct 19 | 121 days |
| Verkazia | cyclosporine | Santen | Severe vernal keratoconjunctivitis, pediatric | 18 Nov 19 | 89 days |
| Revestive | teduglutide | Shire | Short Bowel Syndrome (SBS), pediatrics | 19 Nov 19 | 88 days |
| Takhzyro | lanadelumab | Shire | Hereditary angioedema, prevention | 19 Nov 19 | 88 days |
| Lutathera | lutetium 177 dotatate | Advanced Accelerator Applications | gastroenteropancreatic neuroendocrine tumors (GEP-NETs) | N/A | N/A |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
Both Botox and Revestive are back in negotiations for new indications, while talks on Lutathera have been reactivated, after being closed without an agreement in December 2019.
Completed
The pCPA completed 5 negotiations since the last update for a total of 302 completed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Truxima | rituximab | Teva | rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma | Sep 19 | 153 days |
| Emerade | epinephrine bitartrate | Bausch Health | emergency treatment of anaphylactic reactions | Aug 19 | 184 days |
| Bosulif | bosutinib | Pfizer | chronic myeloid leukemia | Aug 19 | 184 days |
| Xtandi | enzalutamide | Astellas | high risk non-metastatic castrate resistant prostate cancer | Jul 19 | 215 days |
| Kuvan | sapropterin dihydrochloride | BioMarin | Phenylketonuria | May 17 | 1,006 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Signals Decoded:
February saw the completion of the first rituximab biosimilar negotiation, as well as Kuvan, which had been in negotiations for over two-and-a-half years.
Closed
The pCPA closed 1 negotiation since the last update for a total of 49 closed negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | Initiated | Duration* |
|---|---|---|---|---|---|
| Vizimpro | dacomitinib | Pfizer | locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations | Aug 19 | 184 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
Not Negotiated
The pCPA declined negotiation on 1 file since the last update for a total of 74 declined negotiations.
| Brand Name | Generic Name | Manufacturer | Indication | CADTH Date | Time to Decision* |
|---|---|---|---|---|---|
| Nerlynx | neratinib | Knight Therapeutics | Hormone Receptor Positive Breast Cancer | 20 Dec 19 | 57 days |
*Negotiation initiation and completion/closed date assumed to be mid-month; approximate calendar days calculated.
